Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

HGT-3310) for Fabry disease, PLICERA (HGT-3410) for Gaucher Disease and HGT-3510 (formerly referred to as AT2220) for Pompe disease which were in clinical development. The parties have mutually agreed to terminate the collaboration and to return all rights for the three products to Amicus. Alba collaboration for the development of SPD 550 - On October 16, 2009 and following review of Phase 2 data, Shire informed Alba Therapeutics Corporation ("Alba") of its intent to terminate the collaboration. Effective November 15, 2009 Shire will return to Alba all rights to SPD 550 (larazotide cetate for celiac disease), also known as AT-1001. In December 2007 Shire had acquired rights to SPD550 in markets outside of the US and Japan. Business Research Collaboration with Santaris Pharma A/S ("Santaris") on Locked Nucleic Acid ("LNA") Drug Platform - On August 24, 2009 Shire announced that it had entered into a research collaboration with Santaris, to develop its proprietary LNA technology in a range of rare diseases. LNA technology has the benefit of shortened target validation and proof of concept, potentially increasing the speed and lowering the cost of development. As part of the joint research project Santaris will design, develop and deliver pre-clinical LNA oligonucleotides for Shire-selected orphan disease targets, and Shire will have the exclusive right to further develop and commercialize these candidate compounds on a worldwide basis. Legal proceedings - On September 23, 2009 the Company received a subpoena from the US Department of Health and Human Services Office of Inspector General in coordination with the US Attorney for the Eastern District of Pennsylvania, seeking production of documents related to the sales and marketing of ADDERALL XR, DAYTRANA(R) and VYVANSE. Shire is cooperating and respo
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
(Date:7/24/2014)... Wash. , July 24, 2014 Talyst, ... at the 2014 National Association of State Veterans Homes ... . The goal of the NASVH is to ... the benefits, services, long term health care and respect ... With the InSite® Remote Dispensing System, ...
(Date:7/24/2014)... , July 24, 2014  Lazarus Effect, a ... novel interventional devices to facilitate removal of blood ... and Trademark Office has issued a new patent ... the company,s Lazarus Cover TM and ReCover ... ReCover is a single-component stent-retriever (stentriever) with an ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... (Nasdaq: PDEX ) today announced its financial results for ... addition, Pro-Dex announced that its existing credit agreement with Wells ... hired, a product development agreement was signed with a new ... developed product. , Sales for the first quarter ended September ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... company, today announced they have entered into an exclusive ... Australia and New Zealand. An intravenous formulation of ibuprofen, ... the hospital setting. Cumberland Pharmaceuticals received U.S. Food and ...
Cached Medicine Technology:PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 5
(Date:7/25/2014)... July 25, 2014 iTanSmart is a ... iPads. The app provides a tailored approach to eliminating ... dangerous sunburns and skin damage. In his review, Eaton ... and capabilities of iTanSmart. , Eaton begins his ... as a ‘better organized’ and ‘great alternative’ to its ...
(Date:7/25/2014)... to the Addict Him To You Pdf review recently updated ... women how to get the love of the man they ... this book consists of 4 parts, including:, ... (and what to do about it) ,     Part 2: ...     Part 3: How to touch his heart deeply and capture ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As the category ... of Xoçai is to transform and improve individual ... , Adam Paul Green a successful Austin, Texas ... Japan at the end of the July to promote the ... in September 2014. , Eric Worre has been a leader ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 At World ... DC July 19, 17 participating developmentally-disabled teens and young ... even if off-road bicycling, canoeing and hiking can be ... non-profit at the scenic Chesapeake and Ohio Canal ... participating athletes both disabled and able-bodied. Under slightly overcast ...
(Date:7/24/2014)... 2014 iFitDress.com, a renowned wedding dress ... of casual party dresses . According to the ... are now offered at discounted prices, up to 59% ... until August 04. , Most of the casual ... global market. They are popular for special designs, delicate ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... end-stage renal disease who opt for peritoneal dialysis experience no ... a retrospective study at UT Southwestern Medical Center has found. ... body and provides greater mobility than hemodialysis, the more common ... peritoneal dialysis, have a better quality of life and the ...
... HealthDay Reporter , WEDNESDAY, March 2 (HealthDay News) -- ... it plans to remove about 500 unapproved prescription cough, ... drugs have not been evaluated by the FDA for ... take than approved over-the-counter (OTC) drugs that treat these ...
... of death and disease in the U.S., with more than ... And yet teens still smoke. Indeed, smoking usually begins in ... became hooked by the time they were 18. Meanwhile, teens ... While studies have linked cigarette smoking to deficits in ...
... protein p53 is the most frequently mutated in human cancer. ... that it acts primarily as a regulator of how genes ... Pennsylvania School of Medicine show that the protein has at ... sugar glucose, one of body,s main sources of fuel. These ...
... tests and imaging can sometimes help diagnose juvenile idiopathic ... are the most valuable tools in identifying this disease. ... Journal of the American Academy of Orthopaedic Surgeons ... and imaging studies meant to screen for juvenile arthritis ...
... quantitativenot qualitativedata analysis has demonstrated that time-of-flight (TOF) ... detection. Research published in the March issue of ... that oncologic TOF fluorodeoxyglucose (FDG) PET scans yielded ... liver cancers over all contrasts and body mass ...
Cached Medicine News:Health News:Portable, less costly peritoneal dialysis shows no additional catheter risk factors 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 3Health News:Tobacco smoking impacts teens' brains, UCLA study shows 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 3Health News:Penn researchers find new role for cancer protein p53 2Health News:Penn researchers find new role for cancer protein p53 3Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Improved lesion detection with time-of-flight PET scans affirmed 2
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad ... in a wide variety of ophthalmic ... packaged sterile, complete with a safety ... "off " position when not in ...
... The Luminary LASIK Light Probes provide ... that allows the corneal interface to be ... use of the Tindal effect and light ... of interface debris, epithelial deposits, flap edge ...
... EEG system designed to satisfy the needs ... center. Ready to use, Comet XL is ... and Photic Stimulator. Select from various mobile ... your individual needs. These powerful, easy-to-use EEG ...
Medicine Products: